Literature DB >> 7743572

Nondepolarizing neuromuscular blocking drugs and train-of-four fade.

E P McCoy1, F M Connolly, R K Mirakhur, P B Loan, L D Paxton.   

Abstract

The aim of this study was to examine differences in prejunctional effects of different relaxants by measuring the train-of-four (TOF) fade during the onset and recovery of neuromuscular block. The relaxants studied were atracurium (225 micrograms.kg-1), mivacurium (65 micrograms.kg-1) rocuronium (300 micrograms.kg-1) and vecuronium (40 micrograms.kg-1). The TOF ratios were measured at approximate heights of T1 (first response in the TOF) of 90, 75, 50, and 25%. The TOF fade (as shown by lower TOF ratios) increased with a decrease in the T1 during onset of neuromuscular block. Although there was a slightly greater fade with atracurium and rocuronium during the onset of block, the differences among the relaxants were insignificant. It is concluded that the relative prejunctional effects of these relaxants are similar.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7743572     DOI: 10.1007/BF03010679

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  25 in total

1.  Comparison of intubating conditions after administration of Org 9246 (rocuronium) and suxamethonium.

Authors:  R Cooper; R K Mirakhur; R S Clarke; Z Boules
Journal:  Br J Anaesth       Date:  1992-09       Impact factor: 9.166

2.  Train-of-four fade during onset of neuromuscular block with nondepolarising neuromuscular blocking agents.

Authors:  F M Gibson; R K Mirakhur
Journal:  Acta Anaesthesiol Scand       Date:  1989-04       Impact factor: 2.105

Review 3.  Prejunctional and postjunctional cholinoceptors at the neuromuscular junction.

Authors:  W C Bowman
Journal:  Anesth Analg       Date:  1980-12       Impact factor: 5.108

4.  Factors affecting train-of-four fade.

Authors:  A C Pearce; W R Casson; R M Jones
Journal:  Br J Anaesth       Date:  1985-06       Impact factor: 9.166

5.  Vecuronium and d-tubocurarine combination: potentiation of effect.

Authors:  R K Mirakhur; F M Gibson; C J Ferres
Journal:  Anesth Analg       Date:  1985-07       Impact factor: 5.108

6.  Neuromuscular transmission in a mammalian preparation in the absence of blocking drugs and the effect of D-tubocurarine.

Authors:  J I Hubbard; D F Wilson
Journal:  J Physiol       Date:  1973-01       Impact factor: 5.182

7.  Prejunctional and postjunctional effects of tubocurarine and pancuronium in man.

Authors:  A Stanec; T Baker
Journal:  Br J Anaesth       Date:  1984-06       Impact factor: 9.166

8.  Clinical observations on the neuromuscular blocking action of Org 9426, a new steroidal non-depolarizing agent.

Authors:  J M Wierda; A P de Wit; K Kuizenga; S Agoston
Journal:  Br J Anaesth       Date:  1990-04       Impact factor: 9.166

9.  The prejunctional actions of some non-depolarizing blocking drugs.

Authors:  L C Blaber
Journal:  Br J Pharmacol       Date:  1973-01       Impact factor: 8.739

10.  Pretreatment with vecuronium as a prophylactic against post-suxamethonium muscle pain. Comparison with other non-depolarizing neuromuscular blocking drugs.

Authors:  C J Ferres; R K Mirakhur; H J Craig; E S Browne; R S Clarke
Journal:  Br J Anaesth       Date:  1983-08       Impact factor: 9.166

View more
  3 in total

1.  Evaluation of intubating conditions after rocuronium bromide in adults induced with propofol or thiopentone sodium.

Authors:  Moazzam Md Shahnawaz; Bano Shahjahan; Siddiqui Suhail Sarwar
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2011-04

2.  Subparalyzing Doses of Rocuronium Reduce Muscular Endurance without Detectable Effect on Single Twitch Height in Awake Subjects.

Authors:  Jan Gelberg; Peter Bentzer; David Grubb
Journal:  Anesthesiol Res Pract       Date:  2019-05-02

3.  Measuring CMAPs in addition to MEPs can distinguish peripheral ischemia from spinal cord ischemia during endovascular aortic repair.

Authors:  Fabian I Kerkhof; Jan van Schaik; Richard A Massaad; Catharina S P van Rijswijk; Martijn R Tannemaat
Journal:  Clin Neurophysiol Pract       Date:  2020-12-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.